Samento was approved as a medicine in Ecuador in 2004. Government officials have allowed 3 drug claims to be used: anti-inflammatory, antimicrobial and immune system modulator. The Hungarian National Institute of Pharmacy (OGYI), the Hungarian equivalent of the FDA in the US, also approved SAMENTO in 2001 as paramedicament (OTC) pharmaceutical preparation as a “sole or adjunct therapy for rheumatoid diseases, arthritis, and locomotor conditions. It is also approved as a sole or adjunct therapy to enhance immune system function.”
Unlike traditional Cat’s Claw products, the SAMENTO chemotype does not contain Tetracyclic Oxindole Alkaloids (TOAs), a group of chemical antagonists that act upon the central nervous system and can greatly inhibit the positive effect of the Pentacyclic Oxindole Alkaloids (POAs). The POAs primarily affect the immune cells responsible for nonspecific and cellular immunity and demonstrate powerful immune system modulating properties. According to research conducted in Austria, traditional Cat’s Claw products may contain as much as 80% TOAs, and as little as 1% TOAs can cause a 30% reduction in the immune system modulating properties that POAs provide.
As a result of these phytochemical differences between SAMENTO and Cat’s Claw, SAMENTO can be safely used in a broader range of medical conditions. Cat’s Claw acts as an immune system stimulant making it contraindicated in patients with autoimmune disorders, whereas SAMENTO is an immune system modulator. For this reason, SAMENTO can be used to treat all autoimmune disorders.
TOA-Free Cat’s Claw (SAMENTO) and isolated POAs such as mitraphylline, isomytraphylline, isopteropodine, and pteropodine continue to show promising results as they have been studied. The studies below reveal the exciting potential for the use of SAMENTO in various applications.
30 drops twice daily at least 30 minutes before meals (start with 1 drop in 4 oz. of water adding a drop with each dose).